Fig. 3: Tumor responses in cohort 4B in the full analysis set. | Nature Medicine

Fig. 3: Tumor responses in cohort 4B in the full analysis set.

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Fig. 3: Tumor responses in cohort 4B in the full analysis set.

a, Waterfall plot of change in tumor size from baseline. b, Swimmer plot of patient responses over time. Patients included in the waterfall plot (a) were those with baseline and post-baseline measurements; patients classified as non-CR/non-PD are not included (n = 57). One patient had no evaluable CLDN18.2 status and is not shown in either plot. Two patients were missing PD-L1 CPS values and are not shown in the swimmer plot (b). aThis patient had no evaluable CPS status. CR, complete response; H, CLDN18.2 high; I, CLDN18.2 intermediate; PD, progressive disease; PR, partial response; SD, stable disease.

Back to article page